Esiflo Hfa 125 Transhaler is a combination inhalation medication containing Salmeterol (25 mcg) and Fluticasone Propionate (125 mcg), indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta2-adrenergic receptor agonist that provides sustained bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as wheezing and shortness of breath. Fluticasone Propionate is a potent corticosteroid with anti-inflammatory properties that helps decrease airway inflammation, reduce mucus production, and prevent exacerbations. The synergistic action of these two active ingredients offers both immediate symptom relief and long-term control of respiratory conditions. Esiflo Hfa 125 Transhaler is administered via a dry powder inhaler, ensuring targeted delivery to the lungs with minimal systemic absorption, which reduces the risk of systemic side effects. It is intended for regular use and is not suitable for acute bronchospasm or rescue treatment. Patients should be advised to rinse their mouth after inhalation to minimize the risk of oropharyngeal candidiasis. Use of this medication should be under the supervision of a healthcare professional, with dosage tailored to individual patient needs and clinical response.